These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18380634)

  • 1. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center.
    Lee RC; Zou D; Demetrick DJ; Difrancesco LM; Fassbender K; Stewart D
    Value Health; 2008; 11(2):221-30. PubMed ID: 18380634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.
    Johnston KM; Marra CA; Connors JM; Najafzadeh M; Sehn L; Peacock SJ
    Value Health; 2010; 13(6):703-11. PubMed ID: 20561333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
    Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F
    Value Health; 2005; 8(4):462-70. PubMed ID: 16091023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
    Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
    Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Gatwood J; Masaquel A; Fox D; Sheinson D; James C; Li J; Hossain F; Ross R
    J Med Econ; 2024; 27(1):738-745. PubMed ID: 38686393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
    Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
    J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
    Tsutsué S; Tobinai K; Yi J; Crawford B
    PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
    Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
    Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
    Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
    J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.